EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Step Down From Scheduled Inhaled Corticosteroids (ICS) Plus As-Needed Fast-Acting Beta-Agonists (FABA) to As-Needed ICS/FABA: A Systematic Review and Meta-Analysis

Ricardo J Estrada-Mendizabal, John B Hagan, Alex Wonnaparhown, Catherine M Freeman, Christina G Kwong, Gerald W Volcheck, Lisa A Marks, Derek K Chu, Matthew A Rank

The Journal of Allergy and Clinical Immunology: In Practice · 2025

DOI: 10.1016/j.jaip.2025.06.028 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Ricardo J Estrada-Mendizabal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Scottsdale, Ariz. Hauptthemen laut MEDLINE: Asthma, Adrenal Cortex Hormones, Anti-Asthmatic Agents, Adrenergic beta-Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Standard care for stable asthma has been scheduled-dose inhaled corticosteroids (ICSs) plus as-needed fast-acting beta-agonists (FABAs). The efficacy and safety of stepping down from scheduled ICS plus an as-needed FABA compared with as-needed ICS/FABA are unclear. OBJECTIVE: To evaluate the effectiveness and safety of stepping down from scheduled ICS plus as-needed FABA compared with as-needed ICS/FABA in patients with stable asthma. METHODS: We systematically screened MEDLINE, EMBASE, Cochrane Central, and WHO ICTRP for randomized controlled trials comparing outcomes between scheduled ICS plus as-needed FABA and stepping down to as-needed ICS/FABA for patients with stable asthma. Random-effects models-synthesized outcomes included severe exacerbations, asthma control, asthma quality of life, lung function (prebronchodilator FEV1% predicted), cumulative ICS dose (milligrams per year), and severe adverse events. The Grading of Recommendations, Assessment, Development, and Evaluations approach informed certainty of evidence assessments. RESULTS: We included 7 randomized controlled trials (2485 patients). Meta-analysis showed little to no difference between the scheduled and as-needed ICS groups for severe exacerbations (risk ratio, 0.88; 95% CI, 0.67 to 1.17), asthma quality of life (mean difference [MD], -0.11; 95% CI, -0.28 to 0.07), lung function (MD, -1.24; 95% CI, -3.09 to 0.61), and severe adverse events rate (risk ratio, 1.13; 95% CI, 0.43 to 2.95). Asthma control scores favored scheduled ICS (MD, 0.13; 95% CI, 0.04 to 0.22), though the effect was trivial. Cumulative ICS dose was lower with as-needed ICS (MD, -105.36 mg/y; 95% CI, -120.85 to -89.88). On Grading of Recommendations, Assessment, Development, and Evaluations, all outcomes were rated as having moderate certainty of evidence. CONCLUSIONS: In patients with stable asthma on scheduled ICS and as-needed FABA, stepping down to as-needed ICS/FABA resulted in noninferior asthma control and asthma quality of life with reduced cumulative ICS exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAdrenal Cortex HormonesAnti-Asthmatic AgentsAdrenergic beta-AgonistsHumansAdministration, InhalationQuality of LifeDrug Therapy, CombinationRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Anti-inflammatory relieverAs neededAsthmaInhaled corticosteroidsMeta-analysisScheduledStep-downSystematic review

Substanzen

Adrenal Cortex HormonesAnti-Asthmatic AgentsAdrenergic beta-Agonists

Autor:innen und Institutionen

  • Mayo Clinic, Scottsdale, Ariz.
  • Phoenix Children's Hospital, Phoenix, Ariz.
  • McMaster University, Hamilton, Ontario, Canada.
  • Mayo Clinic, Scottsdale, Ariz; Phoenix Children's Hospital, Phoenix, Ariz. Electronic address: rank.matthew@mayo.edu.

Förderung

  • National Heart, Lung, and Blood Institute

Zitieren

APA

Estrada-Mendizabal, R. J., Hagan, J. B., Wonnaparhown, A., Freeman, C. M., Kwong, C. G., Volcheck, G. W., Marks, L. A., Chu, D. K., & Rank, M. A. (2025). Step Down From Scheduled Inhaled Corticosteroids (ICS) Plus As-Needed Fast-Acting Beta-Agonists (FABA) to As-Needed ICS/FABA: A Systematic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.06.028

Vancouver

Estrada-Mendizabal RJ, Hagan JB, Wonnaparhown A, Freeman CM, Kwong CG, Volcheck GW, et al. Step Down From Scheduled Inhaled Corticosteroids (ICS) Plus As-Needed Fast-Acting Beta-Agonists (FABA) to As-Needed ICS/FABA: A Systematic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2025.06.028

BibTeX
@article{EstradaMendizabal2025,
  author = {Estrada-Mendizabal, Ricardo J and Hagan, John B and Wonnaparhown, Alex and Freeman, Catherine M and Kwong, Christina G and Volcheck, Gerald W and Marks, Lisa A and Chu, Derek K and Rank, Matthew A},
  title = {Step Down From Scheduled Inhaled Corticosteroids (ICS) Plus As-Needed Fast-Acting Beta-Agonists (FABA) to As-Needed ICS/FABA: A Systematic Review and Meta-Analysis},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2025},
  doi = {10.1016/j.jaip.2025.06.028}
}
Kostenlos starten →